p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia

被引:0
作者
Malisic, E. [1 ]
Jankovic, R. [1 ]
Slavkovic, D. [1 ]
Milovic-Kovacevic, M. [2 ]
Radulovic, S. [1 ]
机构
[1] Inst Oncol & Radiol Serbia, Dept Expt Oncol, Belgrade 11000, Serbia
[2] Inst Oncol & Radiol Serbia, Dept Med Oncol, Belgrade 11000, Serbia
来源
JOURNAL OF BUON | 2010年 / 15卷 / 01期
关键词
codon; 72; polymorphism; ovarian carcinoma; p53; mutations; EARLY-STAGE; PROGNOSTIC-SIGNIFICANCE; TP53; MUTATIONS; CANCER; CHEMOTHERAPY; EXPRESSION; VARIANTS; BREAST; MODEL;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Ovarian cancer is the leading cause of death from gynecological malignancies. The early stages of this disease are asymptomatic and more than 75% of the cases are diagnosed with regional or distant metastases. p53 gene is frequently mutated in some histological subtypes of ovarian carcinomas. The role of p53 mutations and polymorphic variant of codon 72 in the prognosis of disease is still unclear The aim of this study was to determine the frequency of p53 mutations and polymorphic variants of codon 72 among ovarian carcinoma patients and to correlate them with clinicopathological characteristics of disease. Methods: 54 ovarian carcinoma patients were included in the study. DNA was isolated from tumor tissue by the salting-out method. p53 mutations in exons 4-8 were detected by PCR-SSCP (polymerase chain reaction - single-stranded conformational polymorphism) electrophoresis. Codon 72 polymorphism was assessed by RFLP (restriction fragment-length polymorphism) method. Results: p53 mutations were present in 11 out of 54 patients (20.4%). Twenty-four patients (44.4%) exhibited Arg/Arg, 24 patients (44.4%) Arg/Pro and 6 patients (11.2%) Pro/Pro genotype of 72 codon polymorphism. Correlations between p53 mutations and various clinicopathological characteristics were not found However we observed that the frequency of Pro/Pro genotype was increasing with higher histological grade as well as in advanced compared to localized disease, but without statistical significance. Distribution of p53 gene mutations between Pro/Pro genotype and Arg/Pro plus Arg/Arg genotypes was not statistically significant. Conclusion: Our study suggests that Pro/Pro genotype of 72 codon polymorphism could be an independent prognostic marker in ovarian carcinomas.
引用
收藏
页码:101 / 106
页数:6
相关论文
共 28 条
[11]  
Hogdall EVS, 2002, ANTICANCER RES, V22, P1859
[12]  
Koebel Martin, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S146239940800077X
[13]   Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis [J].
Kurman, Robert J. ;
Visvanathan, Kala ;
Roden, Richard ;
Shih, Ie-Ming .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2008, 198 (04) :351-356
[14]   Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma [J].
Leitao, MM ;
Soslow, RA ;
Baergen, RN ;
Olvera, N ;
Arroyo, C ;
Boyd, J .
GYNECOLOGIC ONCOLOGY, 2004, 93 (02) :301-306
[15]   Characterization of three new serous epithelial ovarian cancer cell lines [J].
Ouellet, Veronique ;
Zietarska, Magdalena ;
Portelance, Lise ;
Lafontaine, Julie ;
Madore, Jason ;
Puiffe, Marie-Line ;
Arcand, Suzanna L. ;
Shen, Zhen ;
Hebert, Josee ;
Tonin, Patricia N. ;
Provencher, Diane M. ;
Mes-Masson, Anne-Marie .
BMC CANCER, 2008, 8 (1)
[16]   Epithelial ovarian cancer: Prevention, diagnosis, and treatment [J].
Partridge, EE ;
Barnes, MN .
CA-A CANCER JOURNAL FOR CLINICIANS, 1999, 49 (05) :297-320
[17]   p53 polymorphic variants at codon 72 exert different effects on cell cycle progression [J].
Pim, D ;
Banks, L .
INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (02) :196-199
[18]  
Powell B, 2000, CLIN CANCER RES, V6, P443
[19]   Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer [J].
Santos, AM ;
Sousa, H ;
Pinto, D ;
Portela, C ;
Pereira, D ;
Catarino, R ;
Duarte, I ;
Lopes, C ;
Medeiros, R .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (07) :958-963
[20]   TP53 and P21 polymorphisms:: Response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer [J].
Santos, AM ;
Sousa, H ;
Portela, C ;
Pereira, D ;
Pinto, D ;
Catarino, R ;
Rodrigues, C ;
Araújo, AP ;
Lopes, C ;
Medeiros, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 340 (01) :256-262